{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:58:49Z","timestamp":1792202329218,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01647-1","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:02:51Z","timestamp":1775466171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-resolution functional mapping of androgen receptor variants"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-6540","authenticated-orcid":false,"given":"Hyeong-Cheol","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5421-3771","authenticated-orcid":false,"given":"Yoojin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-130X","authenticated-orcid":false,"given":"Yumin","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-108X","authenticated-orcid":false,"given":"Kwang Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunho","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-738X","authenticated-orcid":false,"given":"Hyongbum Henry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"1647_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683\u20131722 (2024).","journal-title":"Lancet"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho, I., Day, T. K., Tilley, W. D. & Selth, L. A. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr. Relat. Cancer 23, T179\u2013T197 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"1647_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita, K. & Nonomura, N. Role of androgen receptor in prostate cancer: a review. World J. Mens Health 37, 288\u2013295 (2019).","journal-title":"World J. Mens Health"},{"key":"1647_CR5","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1530\/JME-14-0203","volume":"54","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y., Bolton, E. C. & Jones, J. O. Androgens and androgen receptor signaling in prostate tumorigenesis. J. Mol. Endocrinol. 54, R15\u2013R29 (2015).","journal-title":"J. Mol. Endocrinol."},{"key":"1647_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","volume":"33","author":"Z Culig","year":"2014","unstructured":"Culig, Z. & Santer, F. R. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 33, 413\u2013427 (2014).","journal-title":"Cancer Metastasis Rev."},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/onc.2017.385","volume":"37","author":"W Han","year":"2018","unstructured":"Han, W. et al. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37, 710\u2013721 (2018).","journal-title":"Oncogene"},{"key":"1647_CR8","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","volume":"17","author":"C Massard","year":"2011","unstructured":"Massard, C. & Fizazi, K. Targeting continued androgen receptor signaling in prostate cancer. Clin. Cancer Res. 17, 3876\u20133883 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","volume":"205","author":"AJ Armstrong","year":"2021","unstructured":"Armstrong, A. J. et al. Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses. J. Urol. 205, 1361\u20131371 (2021).","journal-title":"J. Urol."},{"key":"1647_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 79, 263\u2013282 (2021).","journal-title":"Eur. Urol."},{"key":"1647_CR11","first-page":"1288","volume":"20","author":"EM Schaeffer","year":"2022","unstructured":"Schaeffer, E. M. et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 1.2023. J. Natl Compr. Cancer Netw. 20, 1288\u20131298 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/OP.21.00206","volume":"18","author":"N Sayegh","year":"2022","unstructured":"Sayegh, N., Swami, U. & Agarwal, N. Recent advances in the management of metastatic prostate cancer. JCO Oncol. Pract. 18, 45\u201355 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby, D. et al. A new old target: androgen receptor signaling and advanced prostate cancer. Annu. Rev. Pharmacol. Toxicol. 62, 131\u2013153 (2022).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1647_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94707-2","volume":"11","author":"HJ Gim","year":"2021","unstructured":"Gim, H. J., Park, J., Jung, M. E. & Houk, K. N. Conformational dynamics of androgen receptors bound to agonists and antagonists. Sci. Rep. 11, 15887 (2021).","journal-title":"Sci. Rep."},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1073\/pnas.0807282106","volume":"106","author":"JO Jones","year":"2009","unstructured":"Jones, J. O. et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc. Natl Acad. Sci. USA 106, 7233\u20137238 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1647_CR16","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-22-0140","volume":"29","author":"M Shiota","year":"2022","unstructured":"Shiota, M. et al. Androgen receptor mutations for precision medicine in prostate cancer. Endocr. Relat. Cancer 29, R143\u2013R155 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/mend.11.4.9906","volume":"11","author":"J Tan","year":"1997","unstructured":"Tan, J. et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11, 450\u2013459 (1997).","journal-title":"Mol. Endocrinol."},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","volume":"173","author":"J Veldscholte","year":"1990","unstructured":"Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534\u2013540 (1990).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1647_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00499","volume":"2","author":"MD Balbas","year":"2013","unstructured":"Balbas, M. D. et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2, e00499 (2013).","journal-title":"eLife"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg, N. J. et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72, 1494\u20131503 (2012).","journal-title":"Cancer Res."},{"key":"1647_CR21","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","volume":"15","author":"S Prekovic","year":"2016","unstructured":"Prekovic, S. et al. The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol. Cancer Ther. 15, 1702\u20131712 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1647_CR22","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1074\/jbc.M109.039958","volume":"285","author":"DJ van de Wijngaart","year":"2010","unstructured":"van de Wijngaart, D. J. et al. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J. Biol. Chem. 285, 5097\u20135105 (2010).","journal-title":"J. Biol. Chem."},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","volume":"6","author":"X-Y Zhao","year":"2000","unstructured":"Zhao, X.-Y. et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703\u2013706 (2000).","journal-title":"Nat. Med."},{"key":"1647_CR24","first-page":"149","volume":"63","author":"T Hara","year":"2003","unstructured":"Hara, T. et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149\u2013153 (2003).","journal-title":"Cancer Res."},{"key":"1647_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920\u2013926 (2013).","journal-title":"Eur. Urol."},{"key":"1647_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"1647_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00330","volume":"8","author":"ES Antonarakis","year":"2024","unstructured":"Antonarakis, E. S. et al. Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer. JCO Precis. Oncol. 8, e2300330 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243 (2012).","journal-title":"Nature"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1647_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"key":"1647_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","volume":"24","author":"LB Snyder","year":"2025","unstructured":"Snyder, L. B. et al. Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader. Mol. Cancer Ther. 24, 511\u2013522 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1647_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","volume":"40","author":"X Gao","year":"2022","unstructured":"Gao, X. et al. Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 40, 17\u201317 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1647_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(12)60071-3","volume":"380","author":"IA Hughes","year":"2012","unstructured":"Hughes, I. A. et al. Androgen insensitivity syndrome. Lancet 380, 1419\u20131428 (2012).","journal-title":"Lancet"},{"key":"1647_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4274\/jcrpe.galenos.2018.2018.0185","volume":"11","author":"MS Touzon","year":"2019","unstructured":"Touzon, M. S. et al. Androgen insensitivity syndrome: clinical phenotype and molecular analysis in a single tertiary center cohort. J. Clin. Res. Pediatr. Endocrinol. 11, 24\u201333 (2019).","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"1647_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4103\/aja.aja_17_18","volume":"20","author":"SM Yuan","year":"2018","unstructured":"Yuan, S. M. et al. Phenotypic and molecular characteristics of androgen insensitivity syndrome patients. Asian J. Androl. 20, 473\u2013478 (2018).","journal-title":"Asian J. Androl."},{"key":"1647_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/humu.1113","volume":"17","author":"B Gottlieb","year":"2001","unstructured":"Gottlieb, B., Beitel, L. K. & Trifiro, M. A. Variable expressivity and mutation databases: the androgen receptor gene mutations database. Hum. Mutat. 17, 382\u2013388 (2001).","journal-title":"Hum. Mutat."},{"key":"1647_CR37","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862\u2013D868 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1647_CR38","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.3390\/ijms23147556","volume":"23","author":"S Wu","year":"2022","unstructured":"Wu, S., Yu, K., Lian, Z. & Deng, S. Molecular regulation of androgen receptors in major female reproductive system cancers. Int. J. Mol. Sci. 23, 7556 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1647_CR39","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635\u20135652.e5629 (2021).","journal-title":"Cell"},{"key":"1647_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1647_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2017.11.006","volume":"10","author":"Z Gao","year":"2018","unstructured":"Gao, Z., Herrera-Carrillo, E. & Berkhout, B. Delineation of the exact transcription termination signal for type 3 polymerase III. Mol. Ther. Nucleic Acids 10, 36\u201344 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1647_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","volume":"628","author":"J Yan","year":"2024","unstructured":"Yan, J. et al. Improving prime editing with an endogenous small RNA-binding protein. Nature 628, 639\u2013647 (2024).","journal-title":"Nature"},{"key":"1647_CR43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41587-024-02465-z","volume":"43","author":"Y Kim","year":"2025","unstructured":"Kim, Y., Oh, H. C., Lee, S. & Kim, H. H. Saturation profiling of drug-resistant genetic variants using prime editing. Nat. Biotechnol. 43, 1471\u20131484 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1647_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402\u2013410 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1647_CR45","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.cell.2023.03.034","volume":"186","author":"G Yu","year":"2023","unstructured":"Yu, G. et al. Prediction of efficiencies for diverse prime editing systems in multiple cell types. Cell 186, 2256\u20132272.e2223 (2023).","journal-title":"Cell"},{"key":"1647_CR46","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1016\/j.cell.2025.05.046","volume":"188","author":"KS Lee","year":"2025","unstructured":"Lee, K. S. et al. Functional assessment of all ATM SNVs using prime editing and deep learning. Cell 188, 5081\u20135099.e5027 (2025).","journal-title":"Cell"},{"key":"1647_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217\u2013222 (2018).","journal-title":"Nature"},{"key":"1647_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).","journal-title":"Science"},{"key":"1647_CR49","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1101\/gr.097857.109","volume":"20","author":"KS Pollard","year":"2010","unstructured":"Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20, 110\u2013121 (2010).","journal-title":"Genome Res."},{"key":"1647_CR50","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1210\/jc.2016-1990","volume":"101","author":"NC Hornig","year":"2016","unstructured":"Hornig, N. C. et al. Identification of an AR mutation-negative class of androgen insensitivity by determining endogenous AR activity. J. Clin. Endocrinol. Metab. 101, 4468\u20134477 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1647_CR51","doi-asserted-by":"publisher","first-page":"e41913","DOI":"10.7554\/eLife.41913","volume":"8","author":"E Lee","year":"2019","unstructured":"Lee, E. et al. GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. eLife 8, e41913 (2019).","journal-title":"eLife"},{"key":"1647_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.1033","volume":"4","author":"R Wang","year":"2024","unstructured":"Wang, R. et al. Developing a novel enzalutamide-resistant prostate cancer model via AR F877L mutation in LNCaP cells. Curr. Protoc. 4, e1033 (2024).","journal-title":"Curr. Protoc."},{"key":"1647_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13059-015-0864-1","volume":"17","author":"N Lallous","year":"2016","unstructured":"Lallous, N. et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 17, 10 (2016).","journal-title":"Genome Biol."},{"key":"1647_CR54","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"Wyatt, A. W. et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2, 1598\u20131606 (2016).","journal-title":"JAMA Oncol."},{"key":"1647_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.110","volume":"8","author":"L Haertle","year":"2024","unstructured":"Haertle, L. et al. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma. Hemasphere 8, e110 (2024).","journal-title":"Hemasphere"},{"key":"1647_CR56","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cub.2020.11.052","volume":"31","author":"M Ogawa","year":"2021","unstructured":"Ogawa, M., Kawarazaki, Y., Fujita, Y., Naguro, I. & Ichijo, H. FGF21 induced by the ASK1-p38 pathway promotes mechanical cell competition by attracting cells. Curr. Biol. 31, 1048\u20131057.e1045 (2021).","journal-title":"Curr. Biol."},{"key":"1647_CR57","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","volume":"636","author":"J Jee","year":"2024","unstructured":"Jee, J. et al. Automated real-world data integration improves cancer outcome prediction. Nature 636, 728\u2013736 (2024).","journal-title":"Nature"},{"key":"1647_CR58","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","volume":"379","author":"Z Lin","year":"2023","unstructured":"Lin, Z. et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379, 1123\u20131130 (2023).","journal-title":"Science"},{"key":"1647_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29339-9","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X. et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat. Commun. 13, 1669 (2022).","journal-title":"Nat. Commun."},{"key":"1647_CR60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2174\/1389450111314040004","volume":"14","author":"MV Fiandalo","year":"2013","unstructured":"Fiandalo, M. V., Wu, W. & Mohler, J. L. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr. Drug Targets 14, 420\u2013440 (2013).","journal-title":"Curr. Drug Targets"},{"key":"1647_CR61","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1158\/1541-7786.MCR-08-0273","volume":"6","author":"OA O\u2019Mahony","year":"2008","unstructured":"O\u2019Mahony, O. A. et al. Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol. Cancer Res. 6, 1691\u20131701 (2008).","journal-title":"Mol. Cancer Res."},{"key":"1647_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2025.100814","volume":"5","author":"M Herger","year":"2025","unstructured":"Herger, M. et al. High-throughput screening of human genetic variants by pooled prime editing. Cell Genom. 5, 100814 (2025).","journal-title":"Cell Genom."},{"key":"1647_CR63","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","volume":"184","author":"R Cuella-Martin","year":"2021","unstructured":"Cuella-Martin, R. et al. Functional interrogation of DNA damage response variants with base editing screens. Cell 184, 1081\u20131097.e1019 (2021).","journal-title":"Cell"},{"key":"1647_CR64","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"1647_CR65","doi-asserted-by":"publisher","first-page":"W499","DOI":"10.1093\/nar\/gkab319","volume":"49","author":"GH Hwang","year":"2021","unstructured":"Hwang, G. H. et al. PE-Designer and PE-Analyzer: web-based design and analysis tools for CRISPR prime editing. Nucleic Acids Res. 49, W499\u2013W504 (2021).","journal-title":"Nucleic Acids Res."},{"key":"1647_CR66","doi-asserted-by":"publisher","unstructured":"Glaser, M. & Br\u00e4gelmann, J. ESM-Effect: an effective and efficient fine-tuning framework towards accurate prediction of mutation\u2019s functional effect. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.02.03.635741 (2025).","DOI":"10.1101\/2025.02.03.635741"},{"key":"1647_CR67","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1110\/ps.051905906","volume":"15","author":"K Pereira de J\u00e9sus-Tran","year":"2006","unstructured":"Pereira de J\u00e9sus-Tran, K. et al. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15, 987\u2013999 (2006).","journal-title":"Protein Sci."},{"key":"1647_CR68","doi-asserted-by":"publisher","unstructured":"Pereira de Jesus-Tran, K. et al. Crystal structure of human androgen receptor ligand binding domain in complex with dihydrotestosterone. PDB https:\/\/doi.org\/10.2210\/pdb2ama\/pdb (2006).","DOI":"10.2210\/pdb2ama\/pdb"},{"key":"1647_CR69","unstructured":"Oh, H. C. et al. High-resolution functional mapping of androgen receptor variants. NCBI Sequence Read Archive https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1242881 (2025)."}],"updated-by":[{"DOI":"10.1038\/s41551-026-01690-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000}}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01647-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:03:43Z","timestamp":1777359823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01647-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":69,"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01647-1","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41551-026-01690-y","URL":"https:\/\/doi.org\/10.1038\/s41551-026-01690-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On the basis of the findings of this study, Yonsei University has filed a patent listing H.-C.O., J.P., Y. Chang, Y. Cheong and H.H.K. as inventors. H.H.K. is the founder of CisionMed. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}